E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma
Clinical trial NCT02279394 · COMPLETED
Trial details
- NCT number
- NCT02279394
- Sponsor
- Dana-Farber Cancer Institute
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-12-11
- Primary completion
- 2018-12-12
- Enrollment
- 51
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.